Form DEFA14A Aquestive Therapeutics,
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
|
Check the appropriate box:
|
|||
|
☐
|
|
|
Preliminary Proxy Statement
|
|
☐
|
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
|
|
Definitive Proxy Statement
|
|
☒
|
|
|
Definitive Additional Materials
|
|
☐
|
|
|
Soliciting Material under §240.14a-12
|
AQUESTIVE THERAPEUTICS, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
|
☒
|
|
|
No fee required
|
|
☐
|
|
|
Fee paid previously with preliminary materials
|
|
☐
|
|
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SZ Pharma Delivers 600 sqm FDA-Certified Cleanroom Facility in Colombia
- TerraLux and the “Future Islands Initiative “- the Dominican Republic Innovation Lab
- Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share
